Anti-Human DLL4 Recombinant Antibody(Demcizumab)

Product Information

Catalog Number	YR1276
Product Name	Anti-Human DLL4 Recombinant Antibody(Demcizumab)
Molecular Name	Demcizumab
Alias	Anti-DLL4 Recombinant Antibody, Research Grade Demcizumab
CAS Number	1243262-17-0
Target	DLL4[Homo sapiens]
Isotype	IgG2 Kappa
Clonity	Monoclonal
Host	Mouse
Source	CHO Cells
Size	1mg, 5mg
Concentration	1mg/ml
Purity	>95% as determined by SDS-PAGE
Applications	ELISA, FCM, IP, FuncS, IF, Neut, WB
Buffer	PBS, pH7.5
Background	Demcizumab /dɛmˈsɪzʊmæb/ is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene.
Storage	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Note	This product is for research use only.

Cat#	Product Name	Species	Host	Applications	Size	Price